Gsk Plc (GSK.LN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 03-2021 | 12-2020 | 09-2020 | 06-2020 | 03-2020 | |
| Sales | 7,418,000 | 8,739,000 | 8,646,000 | 7,624,000 | 9,090,000 |
| Cost of Goods | 2,480,000 | 3,171,000 | 2,885,000 | 2,449,000 | 3,199,000 |
| Gross Profit | 4,938,000 | 5,568,000 | 5,761,000 | 5,175,000 | 5,891,000 |
| Operating Expenses | 3,245,000 | 6,066,000 | 3,903,000 | 3,935,000 | 3,877,000 |
| Operating Income | 1,693,000 | -498,000 | 1,858,000 | 1,240,000 | 2,014,000 |
| Interest Expense | 201,000 | 203,000 | 198,000 | 229,000 | 229,000 |
| Other Income | 26,000 | 1,522,000 | 11,000 | 1,630,000 | 50,000 |
| Pre-tax Income | 1,518,000 | 821,000 | 1,671,000 | 2,641,000 | 1,835,000 |
| Income Tax | 258,000 | -18,000 | 241,000 | 201,000 | 156,000 |
| Net Income Continuous | 1,260,000 | 839,000 | 1,430,000 | 2,440,000 | 1,679,000 |
| Minority Interests | -187,000 | -162,000 | -186,000 | -177,000 | -114,000 |
| Net Income | $1,073,000 | $677,000 | $1,244,000 | $2,263,000 | $1,565,000 |
| EPS Basic Total Ops | 0.27 | 0.17 | 0.31 | 0.57 | 0.39 |
| EPS Basic Continuous Ops | 0.27 | 0.17 | 0.31 | 0.57 | 0.39 |
| EPS Diluted Total Ops | 0.27 | 0.17 | 0.31 | 0.56 | 0.39 |
| EPS Diluted Continuous Ops | 0.27 | 0.17 | 0.31 | 0.56 | 0.39 |
| EBITDA(a) | $2,080,000 | $3,705,000 | $2,510,000 | $2,870,000 | $2,258,000 |